Dr. Abhishek N. Aphale, MD

Dr. Aphale practices at Fox Chase Cancer Center in Philadelphia, Pennsylvania, part of Thomas Jefferson University.

Dr. Aphale's NPI, 1437300993, was assigned on October 2, 2008. Dr. Aphale graduated from Rutgers Robert Wood Johnson Medical School in 2008. Dr. Aphale holds Pennsylvania license MD447959.

Dr. Aphale's primary practice is Fox Chase Cancer Center, at 333 Cottman Avenue, Philadelphia, PA 19111.

Dr. Aphale's primary practice is Fox Chase Cancer Center in Philadelphia, Pennsylvania, part of Thomas Jefferson University. Dr. Aphale is also affiliated with Temple University Hospital. The medical group on file is Temple Faculty Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Aphale practices, 2 sites in all. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Aphale's primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dr. Aphale is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Aphale's licenses on file in 3 states: Pennsylvania, New Jersey and Michigan.

Dmand AI lists benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, rash, skin cyst and skin discoloration among the conditions Dr. Aphale treats.

CMS data shows 561 Medicare services from Dr. Aphale across 15 procedure codes in 2024, for 247 Medicare patients. Medicare paid $71,264 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 247 Medicare patients who saw Dr. Aphale in 2024. The largest group is 75 to 84, with 107 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Aphale's median patient age at 74, with 50% women.

In 2024, Dr. Aphale wrote 227 Medicare Part D claims for 126 patients. 93% of them were for generic drugs. CMS names the drug for 135 of them, across 8 drugs with 11 or more claims each, at $1,957 in total drug cost. In 2023, CMS named 75 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Aphale for performance year 2024, reported as part of a group. Dr. Aphale accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 57 procedures of melanoma (skin cancer) excision by Dr. Aphale, more than 88% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 15 papers to Dr. Aphale, published from 2003 to 2019. 2010 was the busiest year, with 3. The most frequent topics are Psoriasis, Gene Expression Profiling and Cytokines. Dr. Aphale has published most often in J Invest Dermatol. Dr. Aphale's most frequent co-authors are James Tilford Elder, MD, PhD, John J. Voorhees, MD and Anthony V. Benedetto, DO.

CMS Open Payments shows 63 general payments to Dr. Aphale from 16 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Almirall LLC paid the most, $145.

Dr. Aphale graduated from Rutgers Robert Wood Johnson Medical School in 2008.

Dr. Aphale is in network with 13 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.